Navigation path

Additional tools

  • Print version
  • Decrease text
  • Increase text
  • Choose high contrast version
  • Choose standard colour version

Profile of registrant


Identification number in the register: 7990322925-77
Registration date: 06/01/09 16:12:35

The information on this organisation was last modified on 20/01/15 10:06:56
The date of the last annual update was 05/01/15 14:52:18

Registrant : Organisation or self-employed individual

Name/company name: GlaxoSmithKline
Acronym: GSK
Legal status: Corporation
Website address:


Section: II - In-house lobbyists and trade/professional associations
and more precisely: Companies & groups

Person with legal responsibility

Surname, Name: Mr  Andrew Witty
Position: Chief Executive Officer

Permanent person in charge of EU relations

Surname, Name: Mrs  Sue Middleton
Position: Vice President European Government Affairs

Contact details:

Contact details of organisation's head office: 980 Great West Road 
Brentford, Middlesex TW8 9GS
Telephone number: (+44) 20 8047 5000
Fax number: (+) 
Other contact information: Contact details of Brussels office:

Kunstlaan 46 Avenue Des Arts
1000 Brussels

Tel: +32 (0) 2 282 40 55

Goals / remit

Goals / remit of the organisation: GlaxoSmithKline (GSK) is a research-based pharmaceutical company. Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world.

Headquartered in the UK, we are one of the industry leaders with an estimated seven per cent of the world's pharmaceutical market. We produce medicines that treat major disease areas, including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions, and we market over 25 vaccines to protect against illnesses such as hepatitis A and B, diphtheria, tetanus,whooping cough, typhoid and influenza. GSK also produce consumer health care products including, over-the-counter (OTC) medicines, dental products, smoking control products and nutritional healthcare drinks.

We believe we are the only pharmaceutical company researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria. In 2007, our total community investment was valued at £282 million, equivalent to 3.8 per cent of Group total profit before tax.
The organisation's fields of interests are:
  • global

Number of persons engaged in activities falling under the scope of the Transparency Register

Number of persons: 9
Complementary information: The number of persons reflect the full time employement falling under the scope of the register.

Persons accredited for access to European Parliament premises

First name Surname Start Date End Date
Paulus Lambertus Antonius van Hoof 02/08/14 31/07/15
Sophie Renee Jeanne Marie Philippine Crousse 03/09/14 28/08/15
Karin Jeanette Drielsma 06/08/14 04/08/15
Guilherme Monteiro Ferreira Borges Dos Santos 30/09/14 26/09/15
Diana Mereu 04/10/14 02/10/15
Christian Baracat 26/08/14 19/08/15
Gisela Payeras Bailly 26/08/14 19/08/15
Nicholas Collinge Crosby 08/10/14 06/10/15


Main EU initiatives covered the year before by activities falling under the scope of the Transparency Register:

- to adress unmet medical needs, improve patient safety and strengthen disease prevention in Europe
- to increase Europe´s competitiveness as a location for Research and Development investment

Fields of interest for e-mail alerts on consultations and roadmaps;

Fields declared by the organisation:
  • Competition
  • Consumer Affairs
  • Employment and Social Affairs
  • Enterprise
  • Humanitarian Aid
  • Internal Market
  • Public Health
  • Research and Technology
  • Trade


Information on (i) organisation's membership of any associations/federations/confederations or (ii) relationships to other bodies in formal or informal networks.

EFPIA - European Federation of Pharmaceutical Industries and Associations
Cosmetics Europe

Financial data

Financial year: 01/2013 - 12/2013
Estimated costs to the organisation directly related to representing interests to EU institutions in that year: 600000  € - 700000  €
Amount and source of funding received from the EU institutions in financial year n-1 of registration
Procurement: 0 €
Grants: 0 €
Other (financial) information provided by the organisation:

In 2013, costs associated with lobbying of EU institutions were in the range of 600.000-700.000 euros. This figure is calculated based on the Interinstitutional Agreements published in the Official Journal of 22 July 2011 and includes:
•A percentage of the salaries of the staffers falling under the scope of the Register
•A percentage of the overall costs of running an office in Brussels
•100% of GSK spend on conferences dedicated to “EU Public Affairs”
•A percentage of the costs incurred by the staffers falling under the scope of the Register for travel and accommodation related to EU Public Affairs activities
•100% of the consulting cost spent on EU Public Affairs advice.
In order to avoid double reporting on the Register, this figure excludes trade association membership fees as responsibility for declaring these lies with the respective organisations. The 2013 figure is smaller than GSK’s 2012 figure because there were vacancies. The 2013 figure is 217000 euros.

Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.

The organisation has also declared to be bound to the following other Code: